{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075014","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.358717+00:00","generated_at":"2026-05-17T14:51:55.409825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025","bullets":["Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.","LYMPHIR commercial launch planned for Q4 2025; launch supplies and distribution agreements in place.","Raised $12.5M gross from parent equity offerings in Q3; Citius Oncology raised additional $9M in July 2025.","On July 17, 2025, closed public offering with net proceeds of approximately $7.4M.","Cash and cash equivalents were $112 as of June 30, 2025, subsequently improved by July financings."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075014","json":"https://secwatch.observer/filing/0001213900-25-075014.json","markdown":"https://secwatch.observer/filing/0001213900-25-075014.md","text":"https://secwatch.observer/filing/0001213900-25-075014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/0001213900-25-075014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/ea0252884-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:51:55.409825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}